CDT Invests in CEO-Controlled Peptide Startup Pep'd via $10M Cap SAFE
CDT is trading near its 52-week low of $2.46 (14% above the low) on light trading volume (0.1× avg).
Summary
CDT Equity announced a SAFE note investment in Pep'd Inc., a US peptide telehealth company, with a $10 million valuation cap. The deal expands CDT into the peptide market, but Pep'd is solely owned by CDT's CEO Dr. Andrew Regan, raising related-party concerns. The investment is capital-efficient for CDT, which has been cash-strapped, but the terms are modest and the company's financial distress remains the dominant narrative. This follows a series of dilutive financings and governance red flags, and the market may view this as a distraction or a conflict of interest rather than a value driver.
At the time of this announcement, CDT was trading at $2.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $2.46 to $3,460.60. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.